2024
Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-
2017
Update on Embolization Therapies for Hepatocellular Carcinoma
Kishore S, Friedman T, Madoff DC. Update on Embolization Therapies for Hepatocellular Carcinoma. Current Oncology Reports 2017, 19: 40. PMID: 28421483, DOI: 10.1007/s11912-017-0597-2.Peer-Reviewed Original ResearchConceptsEmbolization therapyHepatocellular carcinomaFuture liver remnant hypertrophyPortal vein tumor thrombusPlanned hepatic resectionStage C diseaseBCLC stage AEarly-stage patientsManagement of patientsSafety of resectionVein tumor thrombusRadiation lobectomyRadiation segmentectomyUnresectable HCCUnifocal diseaseHepatic resectionVein embolizationBCLC stageStage patientsSurvival benefitTumor thrombusAblative optionsB diseaseC diseaseDifferent therapies